Standout Papers

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer 2023 2026 202478
  1. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer (2023)
    Takayuki Yoshino, Maria Di Bartolomeo et al. Nature Communications

Immediate Impact

3 by Nobel laureates 7 from Science/Nature 65 standout
Sub-graph 1 of 22

Citing Papers

Polymeric Nanoparticles for Drug Delivery
2024 Standout
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
2024 Standout
2 intermediate papers

Works of J. Rodríguez being referenced

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
2023 Standout
A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
2020
and 1 more

Author Peers

Author Last Decade Papers Cites
J. Rodríguez 286 350 246 422 83 1.7k
Kenneth McCormick 457 93 215 527 91 2.1k
T. Yamamoto 431 174 205 458 111 2.0k
Bogdan Marek 443 198 93 467 160 1.9k
Seiki Ito 467 138 141 348 121 2.1k
Sirkka-Liisa Karonen 389 204 160 739 44 1.9k
Oliver Blankenstein 514 138 98 1098 86 2.0k
Stefano Giannini 676 471 196 585 49 2.2k
Dariusz Kajdaniuk 393 181 93 400 131 1.7k
Jamshid Alaghband‐Zadeh 357 200 120 481 72 1.7k
Peter Heinz‐Erian 707 209 135 200 68 1.9k

All Works

Loading papers...

Rankless by CCL
2026